I treat children with neuroblastoma, a type of cancer that forms in certain types of nerve tissue. We are focusing on one particular epigenetic biomarker as a determinant of cancer aggressiveness. We are exploring how we can use this epigenetic marker to determine how aggressive a child’s tumor is in order to recommend the most appropriate treatment strategy. We have shown that epigenetic profiling of neuroblastoma tumors can serve as sensitive biomarkers for risk stratifying children and improves our understanding of tumor biology. We are using the same approach to evaluate neuroblastoma epigenetic profiles using blood samples. In contrast to biomarkers that require tumor tissue, liquid biopsies are minimally invasive, clinically convenient, and enable dynamic monitoring.